Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

Indeed, it's often described as a "wonder drug." That hasn’t stopped a torrent of fat phobia and often frankly hateful ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.